Tocilizumab for rheumatoid arthritis (Q24239949)

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Patterns of disability related to joint involvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Comparison of knowledge and psychological well-being between patients with a short disease duration (< or = 1 year) and patients with more established rheumatoid arthritis (> or = 10 years duration).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Infliximab for the treatment of rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Rheumatoid arthritis. Treatment of early disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Cytokine pathways and joint inflammation in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Are American College of Rheumatology 50% response criteria superior to 20% criteria in distinguishing active aggressive treatment in rheumatoid arthritis clinical trials reported since 1997? A meta-analysis of discriminant capacities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Measurement of patient outcome in arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Quality of life in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Rituximab for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Abatacept for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Anakinra for rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Adalimumab for treating rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Tocilizumab: the first interleukin-6-receptor inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in rheumatoid arthritis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

Methods of scoring the progression of radiologic changes in rheumatoid arthritis. Correlation of radiologic, clinical and laboratory abnormalities

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

inferred from DOI database lookup

7 January 2021

based on heuristic

Assessment of patient satisfaction in activities of daily living using a modified Stanford Health Assessment Questionnaire

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331

inferred from DOI database lookup

7 January 2021

based on heuristic

American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis: comment on the article by Felson et al

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD008331